Log in

ASX:PTX - Prescient Therapeutics Stock Price, Forecast & News

0.00 (0.00 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
Now: A$0.03
50-Day Range
MA: A$0.04
52-Week Range
Now: A$0.03
Volume2.00 million shs
Average VolumeN/A
Market Capitalization$10.65 million
P/E RatioN/A
Dividend YieldN/A
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9692 7222



Sales & Book Value

Annual Sales$1.54 million
Cash FlowA$0.02 per share
Book ValueA$0.03 per share



Market Cap$10.65 million
Next Earnings DateN/A

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.

Prescient Therapeutics (ASX:PTX) Frequently Asked Questions

How has Prescient Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Prescient Therapeutics' stock was trading at A$0.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PTX stock has decreased by 22.9% and is now trading at A$0.03. View which stocks have been mosted impacted by Coronavirus.

Has Prescient Therapeutics been receiving favorable news coverage?

Press coverage about PTX stock has trended extremely negative this week, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Prescient Therapeutics earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutPrescient Therapeutics.

Who are some of Prescient Therapeutics' key competitors?

What other stocks do shareholders of Prescient Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prescient Therapeutics investors own include SKYCITY Entertainment Group (SKC) and Finders Resources (FND).

Who are Prescient Therapeutics' key executives?

Prescient Therapeutics' management team includes the following people:
  • Mr. Yatomi-Clarke Steven Lee, MD, CEO & Director
  • Prof. Said M. Sebti M.D., Chief Scientific Officer
  • Dr. Terrence G. Chew M.D., R.A.C., Chief Medical Officer (Age 72)
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Company Sec. (Age 46)
  • Dr. Claudia Gregorio-King, VP of Operations

What is Prescient Therapeutics' stock symbol?

Prescient Therapeutics trades on the ASX under the ticker symbol "PTX."

What is Prescient Therapeutics' stock price today?

One share of PTX stock can currently be purchased for approximately A$0.03.

How big of a company is Prescient Therapeutics?

Prescient Therapeutics has a market capitalization of $10.65 million and generates $1.54 million in revenue each year.  View additional information about Prescient Therapeutics.

What is Prescient Therapeutics' official website?

The official website for Prescient Therapeutics is http://www.ptxtherapeutics.com/.

How can I contact Prescient Therapeutics?

The company can be reached via phone at 61 3 9692 7222.

MarketBeat Community Rating for Prescient Therapeutics (ASX PTX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  32
MarketBeat's community ratings are surveys of what our community members think about Prescient Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel